سعر ارتابينيم 1جم حقن وريد.عضل 2023

Ertapenem-PBI (Pharco B International): ertapenem 1 g powder for intravenous infusion or intramuscular injection, single vial; carbapenem beta-lactam antibiotic.

• Complicated intra-abdominal infections caused by susceptible designated pathogens (adults and children 3 months and older).Population: Adults and paediatric patients >=3 monthsDailyMed (U.S. National Library of Medicine)
• Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis caused by susceptible designated pathogens (adults and children 3 months and older).Population: Adults and paediatric patients >=3 monthsDailyMed (U.S. National Library of Medicine)
• Community acquired pneumonia caused by susceptible designated pathogens (adults and children 3 months and older).Population: Adults and paediatric patients >=3 monthsDailyMed (U.S. National Library of Medicine)

• Most common drug-related adverse experiences in adults: diarrhoea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%) and vaginitis in females (2.1%). Post-marketing: anaphylaxis, hallucinations, altered mental status, dyskinesia, myoclonus, encephalopathy, acute generalised exanthematous pustulosis, teeth staining.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to any component or to other drugs in the same class, or anaphylactic reactions to beta-lactams. IM administration (lidocaine diluent) is contraindicated in hypersensitivity to amide-type local anaesthetics.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactams; enquire about prior reactions to penicillins, cephalosporins and other beta-lactams before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Seizures and other CNS adverse experiences have been reported, most commonly in patients with CNS disorders and/or compromised renal function; adhere to the recommended dosage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with valproic acid or divalproex sodium reduces valproic acid concentrations and increases the risk of breakthrough seizures; concomitant use is generally not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• ProbenecidProbenecid inhibits tubular secretion of ertapenem and increases its plasma concentrations; co-administration is not recommended.DailyMed (U.S. National Library of Medicine)
• Valproic acid / divalproex sodiumCarbapenems reduce valproic acid concentrations, possibly below the therapeutic range, increasing breakthrough seizure risk.DailyMed (U.S. National Library of Medicine)

• Available post-marketing data in pregnancy are insufficient to inform drug-associated risks; animal studies (rats, mice) showed no developmental malformations at exposures up to about 1.2-3 times human exposure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Ertapenem is present in human milk at low levels; there are no data on effects on the breastfed infant or milk production; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ertapenem: Bactericidal: inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins (in E. coli preferentially PBPs 2 and 3); stable to many beta-lactamases including ESBLs but hydrolysed by metallo-beta-lactamases.